Kevin Courtney, M.D., Ph.D.

Kevin Dale Courtney, M.D., Ph.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology.

A native of New Hampshire, Dr. Courtney earned his medical degree and a doctorate in molecular cancer biology at Duke University in North Carolina. He completed internal medicine residency training at the University of California-San Francisco, and then received advanced training through a clinical fellowship in medical oncology at the Dana-Farber Cancer Institute/Dana-Farber Harvard Cancer Center and a postdoctoral research fellowship at Beth Israel Deaconess Medical Center, both in Boston. He also holds a master’s degree in clinical sciences from UT Southwestern.

Certified by the American Board of Internal Medicine in medical oncology, Dr. Courtney joined the UT Southwestern faculty in 2012.

Dr. Courtney’s clinical and translational research efforts focus on prostate and kidney cancer and other genitourinary cancers. His investigations have led to more than 40 publications in peer-reviewed journals, reviews, and editorials.

Dr. Courtney is a member of the American Society of Clinical Oncology. He also serves as a medical advisor to the North Texas Prostate Cancer Coalition, a volunteer organization of prostate cancer survivors and family members.

Graduate School

Duke University School of Medicine (2001)

Other Post Graduate Training

Duke University School of Medicine (2001)

Medical School

Duke University School of Medicine (2002)

Residency

University of California, San Francisco (2005), Internal Medicine

Fellowship

Dana-Farber Cancer Institute (2008), Oncology

• Clinical-translational research in genitourinary oncology
• Industry- and cooperative group-sponsored trials in genitourinary malignancies
• Investigator-initiated clinical trials in kidney cancer
• Investigator-initiated clinical trials in prostate cancer
• Novel biomarkers and therapeutics in prostate and kidney cancer

Featured Publications

Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.

Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, Margulis V, Cadeddu JA, Pedrosa I, DeBerardinis RJ, Malloy CR, Bachoo RM, Maher EA Cell Metab. 2018 Aug

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK J. Clin. Oncol. 2017 Dec JCO2017742627

Targeting Renal Cell Carcinoma with a HIF-2 antagonist.

Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J Nature 2016 Sep

A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer.

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME Clin Genitourin Cancer 2014 Oct

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME Curr Opin Oncol 2012 May 24 3 272-7

The PI3K pathway as drug target in human cancer

Courtney KD, Corcoran RB, Engelman JA Journal of Clinical Oncology 2010 28 1075-83

Optimizing recent advances in metastatic renal cell carcinoma

Courtney KD, Choueiri TK Current Oncology Reports 2009 11 218-226

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.

Courtney KD*, Ma Y*, Diaz de Leon A*, Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, Fatunde O, Arriaga Y, Frankel AE, Kalva S, Zhang S, McKenzie T, Reig Torras O, Figlin RA, Rini BI, McKay RM, Kapur P, Wang T, Pedrosa I, Brugarolas J. Clin Cancer Res. 2019

Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?

Desai NB, Courtney K, Subramaniam RM, Cadeddu JA. Eur Urol. 2019 76 740-742

MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.

Fets L, Driscoll PC, Grimm F, Jain A, Nunes PM, Gounis M, Doglioni G, Papageorgiou G, Ragan TJ, Campos S, Silva Dos Santos M, MacRae JI, O'Reilly N, Wright AJ, Benes CH, Courtney KD, House D, Anastasiou D Nat. Chem. Biol. 2018 Nov 14 11 1032-1042

 Featured Books

PI3K. In Molecular Oncology: Causes of Cancer and Targets for Treatment

Courtney KD, Cantley LC (2012).

The role of ascorbate in metabolism and genotoxicity of chromium (VI).. In Genetic Response to Metals.

Wetterhahn KE, Stearns DM, Misra M, Giangrande PH, Phieffer LS, Kennedy LJ, and Courtney KD. (1995). New York, Marcel Dekker, Inc.

PI3K enters beta-testing.. In Cell Metabolism

Shaywitz AJ, Courtney KD, Patnaik A, and Cantley LC. (2008).

• John W. Boddie, Ph.D. & Joan Reisch, Ph.D. Fund in Prostate Cancer Research in Honor of Dr. Kevin Courtney
  (2019)
• Wheels for Wellness Classic Hero Award of Gratitude from the Wheels for Wellness Foundation and Moncrief Cancer Institute
  (2017)
• UT Southwestern Golden Pager Award
  (2015)
• Career Development Award
  Genentech, Inc. Dana-Farber/Partners Cancer Center (2008)
• Young Investigator Award
  American Society of Clinical Oncology (2008)
• Sigma Xi
  Member (1993)
• Phi Beta Kappa
  Membership (1992)

• American Society of Clinical Oncology (2008)